### Highlights of This Issue 6333

#### SPECIAL FEATURES

**CCR Translations**
- **The Role of Protein Kinase CK2 in Glioblastoma Development**
  - Haitao Ji and Zhimin Lu
  - See related article, p. 6484

**CCR New Strategies**
- **New Strategies in Radiation Therapy: Exploiting the Full Potential of Protons**
  - Radhie Mohan, Anita Mahajan, and Bruce D. Minsky

**Molecular Pathways**
- **Molecular Pathways: Protein Methyltransferases in Cancer**
  - Robert A. Copeland

**CCR Focus**
- **On Masterpieces and Breast Cancer Research**
  - Susan E. Bates
- **Progress in Breast Cancer: Overview**
  - Carlos L. Arteaga
- **Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer**
  - Aditya Bardia and José Baselga
- **Incorporating Genomics into Breast Cancer Clinical Trials and Care**
  - Adel Tabechy, Cynthia X. Ma, Ron Bese, and Matthew J. Ellis
- **Tackling the Diversity of Triple-Negative Breast Cancer**
  - Nicholas C. Turner and Jorge S. Reis-Filho
- **Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer**
  - Xiang H.-F. Zhang, Mario Giuliano, Meghana V. Trivedi, Rachel Schiff, and C. Kent Osborne
- **Can Immunity to Breast Cancer Eliminate Residual Micrometastases?**
  - Mary L. Disis and Sasha E. Stanton

**HUMAN CANCER BIOLOGY**
- **JMJD2B Promotes Epithelial–Mesenchymal Transition by Cooperating with β-Catenin and Enhances Gastric Cancer Metastasis**
  - Li Zhao, Wenjuan Li, Wen Zang, Zhifang Liu, Xia Xu, Han Yu, Qing Yang, and Jihui Jia
- **Germline Variants and Advanced Colorectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study**
- **Contrasting Expression Patterns of Histone mRNA and microRNA 760 in Patients with Gastric Cancer**
- **PI3K Pathway Activation Provides a Novel Therapeutic Target for Pediatric Ependymoma and Is an Independent Marker of Progression-Free Survival**
  - Hazel A. Rogers, Cerys Mayne, Rebecca J. Chapman, John-Paul Kilday, Beth Coyle, and Richard G. Grundy
Autotaxin–Lysophosphatidic Acid Signaling Axis Mediates Tumorigenesis and Development of Acquired Resistance to Sunitinib in Renal Cell Carcinoma
Shih-Chi Su, Xiaoxiao Hu, Patrick A. Kenney, Megan M. Merrill, Kara N. Babaian, Xin Lin, and Christopher G. Wood

Cidofovir: A Novel Antitumor Agent for Glioblastoma
Piotr Hadaczek, Tomoko Ozawa, Liliana Soroceanu, Yasuyuki Yoshida, Lisa Matlaf, Eric Singer, Estefania Fiallos, C. David James, and Charles S. Cobbs

Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma
Ying Zheng, Braden C. McFarland, Denis Drygin, Hao Yu, Susan L. Bellis, Hyunsoo Kim, Markus Bredel, and Etty N. Benveniste
See related article, p. 6335

Shuya Yano, Hiroshi Tazawa, Yuuri Hashimoto, Yasuhiro Shirakawa, Shinji Kuroda, Masahiko Nishizaki, Hirouki Kishimoto, Futoshi Uno, Takeshi Nagasaka, Yasuo Urata, Shunsuke Kagawa, Robert M. Hoffman, and Toshiyoshi Fujiwara

Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models
Scott Portwood, Deepika Lal, Yung-Chun Hsu, Rodrigo Vargas, Megan K. Johnson, Meir Wetzler, Charles P. Hart, and Eunice S. Wang

The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low JWP Expression
Marion A. Salvador, Julien Wicinski, Olivier Caubad, Yves Toiron, Pascal Finetti, Emmanuelle Josselin, Hélène Lelièvre, Laurence Kraus-Berthier, Stéphane Depil, François Bertucci, Yves Collette, Daniel Birnbaum, Emmanuelle Charafé-Jauffret, and Christophe Ginestier

Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
Tao Liu, Wei Hu, Heather J. Dalton, Hyan Jin Choi, Jie Huang, Yu Kang, Sunila Pradeep, Takahito Miyake, Jian H. Song, Yunfei Wen, Chunhua Lu, Chad V. Pecot, Justin Bottsford-Miller, Behrouz Zand, Nicholas B. Jennings, Cristina Ivan, Gary E. Gallick, Keith A. Buggerly, David G. Hangauer, Robert L. Coleman, Michael Frumovitz, and Anil K. Sood

Novel Methylation Biomarker Panel for the Early Detection of Pancreatic Cancer

EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma

End-Therapy Positron Emission Tomography for Treatment Response Assessment in Follicular Lymphoma: A Systematic Review and Meta-analysis
Junhee Pyo, Kyung Won Kim, Heather A. Jacene, Christopher G. Sakellis, Jennifer R. Brown, and Annick D. Van den Abbeele

A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children’s Oncology Group Phase I Consortium Study (ADVL1112)
Patrick A. Thompson, Rachid Drissi, Jodi A. Muscal, Eshini Panditharatna, Maryam Fouladi, Ashish M. Ingle, Charlotte H. Ahern, Joel M. Reid, Tong Lin, Brenda J. Weigel, and Susan M. Blaney
Effects of Adjuvant Chemoradiotherapy on the Frequency and Function of Regulatory T Cells in Patients with Head and Neck Cancer
Patrick J. Schuler, Malgorzata Harasymczuk, Bastian Schilling, Zenichiro Saze, Laura Strauss, Stephan Lang, Jonas T. Johnson, and Theresa L. Whiteside

ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602)
Ronald S. Go, Sandra J. Lee, Donghoon Shin, Steven M. Callister, Dean A. Johe, Robert M. Conry, Ahmad A. Tarihi, and John M. Kirkwood

Photodynamic Therapy with 3-(1'-Hexyloxyethyl) Pyropheophorbide a for Cancer of the Oral Cavity
Nestor Rigual, Gal Shafirstein, Michele T. Cooper, Heinz Baumann, David A. Bellnier, Ulas Sunar, Erin C. Tracy, Daniel J. Rohrbach, Gregory Wilding, Wei Tan, Maureen Sullivan, Mihai Merzianu, and Barbara W. Henderson

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
Andrew X. Zhu, Richard S. Finn, Mary Mulcahy, Jayne Gurtler, Weijing Sun, Jonathan D. Schwartz, Rita P. Dalgal, Adarsh Joshi, Rebecca R. Hozak, Yihuan Xu, Marek Ancukiewicz, Rakesh K. Jain, Francis W. Nugent, Dan G. Duda, and Keith Stuart

A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab

Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers
Ranee Mehra, Fang Zhu, Dong-Hua Yang, Kathy Q. Cai, JoEllen Weaver, Mahendra K. Singh, Anna S. Nikonova, Erica A. Golenski, Douglas B. Flieder, Harry S. Cooper, Miriam Lango, John A. Ridge, and Barbara Burtness

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover shows a human U251-MG glioblastoma cell transfected with 100 nM of non-target siRNA. Phalloidin (green) and DAPI (blue) staining shows organized F-actin and cell morphology. For details, see the article by Zheng and colleagues on page 6484 of this issue.
Clinical Cancer Research

19 (23)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/19/23

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.